Starpharma Holdings Ltd has released a press release.
Annual report and full year financial results
Filed with ASX ·
6ix hasn’t read this filing yet.
Starpharma Holdings Limited on 6ix
Story so far
Earlier from Starpharma
- VivaGel BV NDA advances to next stage of FDA review
- Starpharma licenses VivaGel BV to Mundipharma for Europe
- Mundipharma licenses Starpharmas VivaGel BV
- Appendix 4C - Quarterly Cashflow Report
- Starpharma completes US New Drug Application for VivaGel BV
Later from Starpharma
- AstraZeneca DEP Bcl2/xL inhibitors show compelling efficacy
- DEP irinotecan outperforms in pancreatic cancer model
- Starpharma Investor Presentation for Citi Conference
- DEP products outperform in human pancreatic cancer model
- US VivaGel BV licensed for A$142M milestones plus royalties
Follow Starpharma into a list and get an email when it puts out news.
Follow Starpharma